Voyager Therapeutics, Inc. / Fundamentals
Income statement
- Net revenue
€36.53M - Cost of goods sold
€0.00 - Gross profit
€36.53M - SG&A expenses
€32.00M - R&D expenses
€110.41M - EBITDA
-€102.25M - D&A
€3.62M - EBIT
-€105.87M - Interest expenses
€0.00 - EBT
-€92.02M - Tax expenses
€582.58K - Net income
-€92.61M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
-€15.61M - Changes in working capital
-€4.23M - Operating cash flow
-€97.51M - Capex
€1.87M - Other investing cash flow
€0.00 - Net investing cash flow
€68.88M - Total cash dividends paid
€0.00 - Issuance of common stock
€0.00 - Debt repayment
€0.00 - Other financing cash flow
€642.64K - Net financing cash flow
€1.02M - Foreign exchange effects
€0.00 - Net change in cash
-€27.62M - Cash at end of period
€40.17M - Free cash flow
-€95.65M
Balance sheet
- Cash and cash equivalents
€37.70M - Cash and short-term investments
€184.98M - Total receivables
€2.17M - Inventory
€0.00 - Other current assets
€8.38M - Total current assets
€195.53M - Property, plant & equipment
€38.52M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€42.32M - Other non-current assets
€0.00 - Total non-current assets
€80.83M - Total assets
€276.36M - Accounts payable
€1.55M - Short-term debt
€6.55M - Other current liabilities
€10.32M - Total current liabilities
€36.02M - Long-term debt
€55.89M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€858.00K - Total non-current liabilities
€31.04M - Total liabilities
€67.06M - Common stock
€48.05K - Retained earnings
-€335.12M - Other equity
-€189.62K - Total equity
€209.30M - Total liabilities and shareholders' equity
€276.36M
Company information
- Market capitalization
€139.71M - Employees
172 - Enterprise Value
€164.24M
Company ratios
- Gross margin
-
100.0% Much better than peer group: -222.6% - EBITDA margin
-
-279.9% Much better than peer group: -5,271.2% - EBIT margin
-
-289.8% Much better than peer group: -5,668.0% - EBT margin
-
-251.9% Much better than peer group: -283,877.5% - Net margin
-
-253.5% Much better than peer group: -4,715.4% - ROE
-
-44.2% Much better than peer group: -89.6% - ROA
-
-33.5% Much better than peer group: -58.8% - Asset turnover
-
13.2% Worse than peer group: 25.4% - FCF margin
-
-272.0% Much better than peer group: -3,517.6% - FCF yield
-71.1% - Efficiency ratio
379.9% - Net sales per employee
-
€212.41K - Net income per employee
-
-€538.42K